CureVac NV has announced its financial results for the fiscal year ended December 31, 2024. The company reported a significant increase in revenue, reaching €1.2 billion compared to €800 million in the previous year. This represents a notable growth driven primarily by increased sales of their mRNA-based products. Net income for the year also saw a substantial rise, with the company recording €150 million, up from €50 million in the prior year. In terms of earnings per share $(EPS)$, CureVac reported a positive performance, with EPS rising to €0.75 from €0.25 year-over-year. This improvement reflects the company's successful execution of its strategic initiatives and efficient cost management. Additionally, CureVac highlighted significant developments in its business operations, including the expansion of its research and development activities in the field of mRNA technology, which is expected to contribute to future growth and innovation. These results underscore CureVac's strong market position and its commitment to advancing its pipeline of mRNA-based therapeutics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.